Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Dostarlimab (Primary) ; TSR 033 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms CITRINO
  • Sponsors TESARO
  • Most Recent Events

    • 09 Nov 2018 According to a TESARO media release, preliminary results (n=30) of the monotherapy dose-escalation portion from this study, were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C.
    • 09 Nov 2018 Preliminary results (n=30) of the monotherapy dose-escalation portion from this study presented in a TESARO media release.
    • 02 Aug 2018 According to a TESARO media release, data from this trial will be presented at the The Society for Immunotherapy of Cancer's (SITC) Annual Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top